The aim of the study was to assess the influence of drugs included in ALL induction therapy on antigen expression of blast cells which are common targets for immunotherapy (CD19, CD20) or possess the potential to impact its effectiveness (CD58). This evidence concerns the gene CD58 and acute lymphoblastic leukemia.